Serial Number
88299485
Owner
Cadex Genomics, Corp.Attorney
Alison M. CalessFirst Use Date
Apr 16, 2019
Filing Date
Feb 13, 2019
ALIBREX Trademark
Serial Number: 88299485 • Registration: 6159041
Trademark Classes
Class 5 - Pharmaceuticals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Class 42 - Computer & Scientific
Scientific and technological services; industrial analysis and research services
Class 44 - Medical Services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Owner Contact Info
541 Jefferson Avenue, Suite 100
Redwood City, CA 94063
Entity Type: 03
Legal Representation
Correspondence Address
Alison M. Caless Cantor Colburn LLP
20 Church Street
Floor 22
Hartford, CT 06103
United States
Trademark Details
Filing Date
February 13, 2019
Registration Date
September 22, 2020
First Use Anywhere
April 16, 2019
First Use in Commerce
April 16, 2019
Published for Opposition
December 10, 2019
Goods & Services
Medical testing for diagnostic or treatment purposes, namely, for the purpose of testing of bodily fluids used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy
Medical diagnostic assays for testing of bodily fluids, namely, assays used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy; Medical diagnostic test media in the form of reagents used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy; medical diagnostic kits comprised of medical diagnostic reagents and assays used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy
Medical and scientific research in the field of medical diagnostic assays and clinical testing services for the purpose of testing of bodily fluids used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy
